Is Novo Nordisk Stock a Buy Now?

Novo Nordisk's shares have declined 58% over the past 18 months, primarily due to intensified competition from Eli Lilly's Zepbound, lowered guidance, and clinical setbacks, despite reporting strong H1 sales of DKK 154.9 billion ($24.4 billion) and a 23% EPS increase. To counter these headwinds, the company is strategically expanding its pipeline with promising assets such as the licensed triple agonist UBT251 and internally developed oral semaglutide, alongside a recent label expansion for Wegovy in MASH. With a forward P/E of 13.1, below the healthcare industry average, the stock appears reasonably valued, suggesting potential for a rebound.

Analysis

Novo Nordisk (NVO) presents a complex profile of strong current fundamentals juxtaposed with significant market headwinds and a depressed valuation. Despite a 58% share price decline over the past 18 months, the company reported robust first-half performance with net sales increasing 15% year-over-year to 154.9 billion DKK and earnings per share growing 23% to 12.49 DKK. The negative sentiment is primarily driven by lowered fiscal 2025 guidance, underperformance of its core GLP-1 medicines against expectations, and intense competition from Eli Lilly's Zepbound. Clinical results for its CagriSema candidate, while positive, also failed to meet the high bar set by management and analysts. In response, Novo Nordisk has initiated a strategic pivot, marked by a CEO change and aggressive pipeline enhancement. Key initiatives include licensing UBT251, a promising triple-agonist that demonstrated a 15.1% weight loss in a Phase 1b study, advancing its internal candidate amycretin to Phase 3, and seeking approval for an oral version of semaglutide. Furthermore, the recent label expansion for Wegovy into the MASH market opens a material new revenue stream. From a valuation perspective, the stock's forward price-to-earnings ratio of 13.1 stands at a notable discount to the healthcare industry average of 16.5, suggesting the market has priced in the risks but may be overlooking the potential of its strategic turnaround.

Key Decisions for Investors

• Consider the current forward P/E of 13.1, a discount to the sector average, as a potential entry point for a long-term position, banking on a successful execution of the company's pipeline and strategic initiatives.
• Closely monitor key upcoming catalysts, including clinical trial data for the licensed triple-agonist UBT251 and internally developed amycretin, as these will be critical validation points for the company's R&D strategy.
• Acknowledge the significant and ongoing competitive pressure from Eli Lilly's Zepbound, which continues to post strong sales and clinical results, and factor this dynamic into risk assessment and position sizing.
• Evaluate the market uptake and revenue contribution from Wegovy's recent label expansion for MASH, as this represents a near-term avenue for growth diversification beyond the core weight management and diabetes markets.